A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer

NCT01187212 Phase 2 COMPLETED

This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.

Details

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	COMPLETED
Enrolment	195
Start date	2010-08
Completion	2014-08

Conditions

• Malignant Neoplasm of Stomach
• Effects of Chemotherapy

Interventions

• Capecitabine/Cisplatin + Sorafenib
• Capecitabine/Cisplatin

Primary outcomes

• Progression-free survival — 2 years

Countries

South Korea